Cargando…

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study

BACKGROUND: Concurrent chemoradiotherapy (CCRT) is expected to improve local and systemic disease control and has been established as a standard therapy for several types of solid tumors. Considering the benefits of frontline radiation and pegaspargase in localized extranodal natural killer (NK)/T‐c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hua, Wang, Liang, Li, Chun, Wuxiao, Zhijun, Chen, Guanjun, Luo, Wei, Lu, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Hematologic Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648361/ https://www.ncbi.nlm.nih.gov/pubmed/32627928 http://dx.doi.org/10.1634/theoncologist.2020-0144

Ejemplares similares

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials
por: Reinartz, Gabriele, et al.
Publicado: (2020)

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
por: Doukas, Peter G, et al.
Publicado: (2023)

Characteristics and prognosis of distant metastasis after primary treatment for early‐stage extranodal nasal‐type natural killer/T‐cell lymphoma from the China Lymphoma Collaborative Group database
por: Zheng, Xuan, et al.
Publicado: (2022)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
por: Danilov, Alexey V, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019)

Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B‐Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment
por: Liu, Hui, et al.
Publicado: (2018)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram
por: Liu, Junqi, et al.
Publicado: (2023)

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study
por: Musimar, Zola, et al.
Publicado: (2023)

The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type
por: Lee, Jieun, et al.
Publicado: (2013)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies
por: Samuelson, Clare, et al.
Publicado: (2016)

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation
por: Kubeczko, Marcin, et al.
Publicado: (2016)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)

More Insights on the Use of γ‐Secretase Inhibitors in Cancer Treatment
por: López‐Nieva, Pilar, et al.
Publicado: (2020)

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
por: Goyal, Gaurav, et al.
Publicado: (2022)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
por: Kaplan, Henry G, et al.
Publicado: (2022)

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life
por: Jensen, Christopher E, et al.
Publicado: (2022)

A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
por: Zhao, Janice, et al.
Publicado: (2022)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
por: Gill, Harinder, et al.
Publicado: (2010)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma
por: Kim, Tae Hyung, et al.
Publicado: (2016)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Extranasal natural killer/T-cell lymphoma initially presenting as myelofibrosis
por: Jang, Woori, et al.
Publicado: (2016)

Salvage radiotherapy improves survival in patients with locoregionally relapsed stage IE–IIE extranodal natural killer/T-cell lymphoma, nasal type
por: Tong, Qin, et al.
Publicado: (2018)

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma
por: Luo, Jialin, et al.
Publicado: (2016)

A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China
por: Liang, Rong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1afh3jleac683pv9kh9gbprk4j